8-K: VSee Health Faces Nasdaq Delisting Threat

VSee Health, Inc. received a Nasdaq deficiency letter due to its common stock trading below $1.00, failure to file quarterly reports, and insufficient stockholders' equity.

Summary

• VSee Health, Inc. (VSEE) received a Nasdaq Staff Deficiency Letter on September 24, 2025, indicating non-compliance with listing rules.
• The company's common stock bid price closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• VSee has an initial period of 180 calendar days, until March 23, 2026, to regain compliance with the minimum bid price rule.
• To regain bid price compliance, the common stock must close at $1.00 per share or more for a minimum of ten consecutive business days.
• The company is also non-compliant with Nasdaq Listing Rule 5250(c)(1) due to its failure to timely file Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025.
• Additionally, VSee is not in compliance with Nasdaq Listing Rule 5550(b)(1) because its stockholders' equity fell below the $2,500,000 required minimum as of December 31, 2024.
• Failure to regain compliance could lead to the delisting of the company's common stock and public warrants from The Nasdaq Capital Market.

Sentiment

Score: 1

Explanation: The filing details multiple severe non-compliance issues with Nasdaq listing rules, including a low bid price, failure to file financial reports, and insufficient stockholders' equity, all of which point to significant operational and financial distress and a high risk of delisting.

Negatives

• Common stock bid price closed below $1.00 for 30 consecutive business days, violating Nasdaq's minimum bid price rule.
• Failure to timely file Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025.
• Stockholders' equity fell below the $2,500,000 minimum required for continued listing as of December 31, 2024.
• Faces a significant risk of delisting from The Nasdaq Capital Market due to multiple non-compliance issues.

Risks

• No assurance that the company will meet the bid price requirement during any compliance period or in the future.
• Uncertainty regarding the company's ability to meet other Nasdaq compliance standards.
• Nasdaq may not grant the company any relief from delisting as necessary.
• Potential inability to agree to or ultimately meet applicable Nasdaq requirements for any such relief.
• Delisting of common stock and public warrants could lead to a very limited market for these securities.
• Stockholders and public warrant holders may find it difficult to sell their shares and warrants.
• The trading price of the company's common stock and public warrants may be adversely affected by delisting.

Future Outlook

VSee Health intends to monitor the bid price of its common stock and consider available options if its stock does not trade at a level likely to result in regaining compliance by March 23, 2026. The company is also working on remedying deficiencies related to timely filing of Form 10-Q and insufficient stockholders' equity, though there is no assurance of eligibility for additional compliance periods or continued listing.

Management Comments

• "The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq's minimum bid price rule by March 23, 2026."
• "The Company is working on remedying these deficiencies [Form 10-Q filings and stockholders' equity], but there can be no assurance that the Company will be eligible for the additional 180 calendar day compliance period, or that the Staff would grant the Company's request for continued listing subsequent to any delisting notification."

Industry Context

This announcement reflects company-specific operational and financial challenges rather than broader industry trends. While the telehealth sector has seen fluctuations, VSee Health's issues with financial reporting and equity levels point to internal governance and performance concerns that are not necessarily indicative of the wider industry.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Face a risk of delisting, which could lead to a limited market for shares, difficulty selling shares, and an adverse effect on trading price.
• Public Warrant Holders: Face a risk of delisting, which could lead to a limited market for warrants, difficulty selling warrants, and an adverse effect on trading price.
• Employees: May experience increased uncertainty regarding the company's future operations and stability.
• Creditors: May face increased risk due to the company's financial distress and potential loss of Nasdaq listing.

Next Steps

• Monitor the bid price of common stock.
• Consider available options to regain bid price compliance by March 23, 2026.
• Work on remedying deficiencies related to timely filing of Form 10-Q.
• Work on remedying deficiencies related to insufficient stockholders' equity.
• Potentially effect a reverse stock split if necessary to cure bid price deficiency.
• Appeal Nasdaq's determination if a delisting notification is received.

Key Dates

Recommendation

The company faces severe and multiple non-compliance issues with Nasdaq, including a prolonged low bid price, failure to file critical financial reports, and insufficient stockholders' equity. These factors indicate significant financial distress and a high probability of delisting, which would severely impair liquidity and valuation. The outlook is highly negative with no clear path to immediate recovery or sustained compliance, making the stock a strong sell to mitigate further losses.

Keywords

VSee Health, VSEE, Nasdaq, Delisting, Minimum Bid Price, Form 10-Q, Stockholders' Equity, Compliance, Telehealth, Healthcare Technology